WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

Search

Compass Pathways Plc ADR

Cerrado

3.08 11.19

Resumen

Variación precio

24h

Actual

Mínimo

2.75

Máximo

3.1

Métricas clave

By Trading Economics

Ingresos

-4.4M

-43M

BPA

-0.63

Empleados

166

EBITDA

513K

-41M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+533.33% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-83M

259M

Apertura anterior

-8.11

Cierre anterior

3.08

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Compass Pathways Plc ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 18:52 UTC

Principales Movimientos del Mercado

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Comparación entre iguales

Cambio de precio

Compass Pathways Plc ADR Esperado

Precio Objetivo

By TipRanks

533.33% repunte

Estimación a 12 meses

Media 17.67 USD  533.33%

Máximo 45 USD

Mínimo 9 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compass Pathways Plc ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.91 / 3.105Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.